QC-308

QC-308 potently inhibits HO-1 activity in rat spleen microsomes with an IC₅₀ of 0.27 μM, and inhibits HO-2 activity in rat brain microsomes with an IC₅₀ of 0.46 μM^[1].
QC-308 binds to truncated recombinant hHO‑1 and hHO‑2, alters the heme environment of both proteins, and inhibits heme degradation in a dose-dependent manner; the hHO‑2 system retains 87.2% of intact heme, while the hHO‑1 system reduces the initial heme degradation rate to 9.8% of the control group and retains 71.6% of intact heme simultaneously^[1].

QC-308 binds to truncated recombinant hHO-1 through a "double-prong" mode, occupying two independent hydrophobic pockets and coordinating with heme iron, thereby forming a stable inhibitor-enzyme complex^[1].
QC-308 (1.00×10^‑9-1.00×10^‑3 M; 5 days) exhibits a senescence-dependent slight reduction in viability in senescent primary mouse FAPs; it does not show a senescence-specific decrease in viability in senescent primary mouse SCs; and it induces a senescence-dependent decline in viability in senescent human skeletal myoblasts^[2].
QC-308 (1-500 μM; 72 h) does not exhibit senolytic activity in senescent mouse skin fibroblasts and human lung fibroblasts (IMR-90 cells) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.